{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,25]],"date-time":"2026-09-25T18:42:04Z","timestamp":1790361724392,"version":"4.1.0"},"reference-count":134,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2018,3,1]],"date-time":"2018-03-01T00:00:00Z","timestamp":1519862400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,11,4]],"date-time":"2019-11-04T00:00:00Z","timestamp":1572825600000},"content-version":"vor","delay-in-days":613,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Annals of Oncology"],"published-print":{"date-parts":[[2018,3]]},"DOI":"10.1093\/annonc\/mdx413","type":"journal-article","created":{"date-parts":[[2017,8,1]],"date-time":"2017-08-01T11:17:48Z","timestamp":1501586268000},"page":"544-562","source":"Crossref","is-referenced-by-count":70,"title":["ESMO Consensus Conference on malignant lymphoma: general perspectives and recommendations for the clinical management of the elderly patient with malignant lymphoma"],"prefix":"10.1016","volume":"29","author":[{"given":"C.","family":"Buske","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Hutchings","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Ladetto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"V.","family":"Goede","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"U.","family":"Mey","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"P.","family":"Soubeyran","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Spina","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R.","family":"Stauder","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Trn\u011bn\u00fd","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"U.","family":"Wedding","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"P.","family":"Fields","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christian","family":"Buske","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martin","family":"Dreyling","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andr\u00e9s J M","family":"Ferreri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul","family":"Fields","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gianluca","family":"Gaidano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Valentin","family":"Goede","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martin","family":"Hutchings","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marco","family":"Ladetto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Steven","family":"Le Gouill","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stefano","family":"Luminari","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ulrich","family":"Mey","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter","family":"de Nully Brown","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Pfreundschuh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christiane","family":"Pott","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Norbert","family":"Schmitz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pierre","family":"Soubeyran","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michele","family":"Spina","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Reinhard","family":"Stauder","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna Sureda","family":"Balari","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marek","family":"Trn\u011bn\u00fd","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gustaaf","family":"van Imhoff","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jan","family":"Walewski","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ulrich","family":"Wedding","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alberto","family":"Zam\u00f2","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emanuele","family":"Zucca","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1093\/annonc\/mdx413_bb0010","unstructured":"Eurostat. News release: Nearly 27 million people aged 80 or over in the European Union 2016; http:\/\/ec.europa.eu\/eurostat\/documents\/2995521\/7672228\/3-29092016-AP-EN.pdf\/4b90f6bb-43c1-45ed-985b-dfbe9564157a (25 November 2016, date last accessed)."},{"key":"10.1093\/annonc\/mdx413_bb0015","unstructured":"European Commission, The 2015 Ageing Report 2015; http:\/\/europa.eu\/epc\/sites\/epc\/files\/docs\/pages\/ageing_report_2015_en.pdf (8 July 2016, date last accessed)."},{"key":"10.1093\/annonc\/mdx413_bb0020","author":"Howlader","year":"2016","journal-title":"SEER Cancer Statistics Review 1975-2013 National Cancer Institute Bethesda MD based on November 2015 SEER data submission"},{"key":"10.1093\/annonc\/mdx413_bb0025","unstructured":"Tirol Kliniken Tumor register Tyrol 2016; https:\/\/www.iet.at\/page.cfm?vpath=index (22 November 2016, date last accessed)."},{"key":"10.1093\/annonc\/mdx413_bb0030","doi-asserted-by":"crossref","first-page":"675","DOI":"10.1093\/annonc\/mdt592","article-title":"On-going clinical trials for elderly patients with a hematological malignancy: are we addressing the right end points?","volume":"25","author":"Hamaker","year":"2014","journal-title":"Ann Oncol"},{"key":"10.1093\/annonc\/mdx413_bb0035","doi-asserted-by":"crossref","first-page":"1290","DOI":"10.1200\/JCO.2010.30.6985","article-title":"Implementing a geriatric assessment in cooperative group clinical cancer trials: CALGB 360401","volume":"29","author":"Hurria","year":"2011","journal-title":"J Clin Oncol"},{"key":"10.1093\/annonc\/mdx413_bb0040","doi-asserted-by":"crossref","first-page":"3711","DOI":"10.1200\/JCO.2013.49.6125","article-title":"End points and trial design in geriatric oncology research: a joint European organisation for research and treatment of cancer\u2013Alliance for Clinical Trials in Oncology\u2013International Society Of Geriatric Oncology position article","volume":"31","author":"Wildiers","year":"2013","journal-title":"J Clin Oncol"},{"key":"10.1093\/annonc\/mdx413_bb0045","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1086\/321805","article-title":"Summary of the guidelines for preventing opportunistic infections among hematopoietic stem cell transplant recipients","volume":"33","author":"Dykewicz","year":"2001","journal-title":"Clin Infect Dis"},{"issue":"Suppl 5","key":"10.1093\/annonc\/mdx413_bb0050","doi-asserted-by":"crossref","first-page":"v78","DOI":"10.1093\/annonc\/mdv303","article-title":"Chronic lymphocytic leukaemia: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up","volume":"26","author":"Eichhorst","year":"2015","journal-title":"Ann Oncol"},{"issue":"Suppl 5","key":"10.1093\/annonc\/mdx413_bb0055","doi-asserted-by":"crossref","first-page":"v116","DOI":"10.1093\/annonc\/mdv304","article-title":"Diffuse large B-cell lymphoma (DLBCL): ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up","volume":"26","author":"Tilly","year":"2015","journal-title":"Ann Oncol"},{"issue":"Suppl 5","key":"10.1093\/annonc\/mdx413_bb0060","doi-asserted-by":"crossref","first-page":"v83","DOI":"10.1093\/annonc\/mdw400","article-title":"Newly diagnosed and relapsed follicular lymphoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up","volume":"27","author":"Dreyling","year":"2016","journal-title":"Ann Oncol"},{"issue":"Suppl 4","key":"10.1093\/annonc\/mdx413_bb0065","doi-asserted-by":"crossref","first-page":"iv62","DOI":"10.1093\/annonc\/mdx223","article-title":"Newly diagnosed and relapsed mantle cell lymphoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up","volume":"28","author":"Dreyling","year":"2017","journal-title":"Ann Oncol"},{"issue":"Suppl 5","key":"10.1093\/annonc\/mdx413_bb0070","doi-asserted-by":"crossref","first-page":"v108","DOI":"10.1093\/annonc\/mdv201","article-title":"Peripheral T-cell lymphomas: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up","volume":"26","author":"d'Amore","year":"2015","journal-title":"Ann Oncol"},{"key":"10.1093\/annonc\/mdx413_bb0075","doi-asserted-by":"crossref","first-page":"1800","DOI":"10.1093\/annonc\/mdu208","article-title":"Optimization of rituximab for the treatment of DLBCL (I): dose-dense rituximab in the DENSE-R-CHOP-14 trial of the DSHNHL","volume":"25","author":"Murawski","year":"2014","journal-title":"Ann Oncol"},{"key":"10.1093\/annonc\/mdx413_bb0080","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1016\/j.ctrv.2009.10.008","article-title":"EORTC Elderly Task Force experts' opinion for the treatment of colon cancer in older patients","volume":"36","author":"Pallis","year":"2010","journal-title":"Cancer Treat Rev"},{"key":"10.1093\/annonc\/mdx413_bb0085","doi-asserted-by":"crossref","first-page":"752","DOI":"10.1093\/annonc\/mdm541","article-title":"Prognostic factors for hematotoxicity of chemotherapy in aggressive non-Hodgkin's lymphoma","volume":"19","author":"Ziepert","year":"2008","journal-title":"Ann Oncol"},{"key":"10.1093\/annonc\/mdx413_bb0090","doi-asserted-by":"crossref","DOI":"10.1093\/jnci\/dju129","article-title":"Recommended patient-reported core set of symptoms to measure in adult cancer treatment trials","volume":"106","author":"Reeve","year":"2014","journal-title":"J Natl Cancer Inst"},{"key":"10.1093\/annonc\/mdx413_bb0095","doi-asserted-by":"crossref","first-page":"837","DOI":"10.1182\/blood-2013-09-524108","article-title":"An enhanced International Prognostic Index (NCCN-IPI) for patients with diffuse large B-cell lymphoma treated in the rituximab era","volume":"123","author":"Zhou","year":"2014","journal-title":"Blood"},{"key":"10.1093\/annonc\/mdx413_bb0100","doi-asserted-by":"crossref","first-page":"2203","DOI":"10.1016\/j.ejca.2007.06.001","article-title":"Quality-of-life in elderly patients with cancer: a short review","volume":"43","author":"Wedding","year":"2007","journal-title":"Eur J Cancer"},{"key":"10.1093\/annonc\/mdx413_bb0105","doi-asserted-by":"crossref","first-page":"2595","DOI":"10.1200\/JCO.2013.54.8347","article-title":"International Society of Geriatric Oncology consensus on geriatric assessment in older patients with cancer","volume":"32","author":"Wildiers","year":"2014","journal-title":"J Clin Oncol"},{"key":"10.1093\/annonc\/mdx413_bb0110","doi-asserted-by":"crossref","first-page":"1922","DOI":"10.1093\/annonc\/mdq687","article-title":"EORTC workshop on clinical trial methodology in older individuals with a diagnosis of solid tumors","volume":"22","author":"Pallis","year":"2011","journal-title":"Ann Oncol"},{"key":"10.1093\/annonc\/mdx413_bb0115","doi-asserted-by":"crossref","first-page":"e115060","DOI":"10.1371\/journal.pone.0115060","article-title":"Screening for vulnerability in older cancer patients: the ONCODAGE Prospective Multicenter Cohort Study","volume":"9","author":"Soubeyran","year":"2014","journal-title":"PLoS One"},{"key":"10.1093\/annonc\/mdx413_bb0120","doi-asserted-by":"crossref","first-page":"288","DOI":"10.1093\/annonc\/mdu210","article-title":"Screening tools for multidimensional health problems warranting a geriatric assessment in older cancer patients: an update on SIOG recommendations","volume":"26","author":"Decoster","year":"2015","journal-title":"Ann Oncol"},{"key":"10.1093\/annonc\/mdx413_bb0125","doi-asserted-by":"crossref","first-page":"2166","DOI":"10.1093\/annonc\/mdr587","article-title":"Screening older cancer patients: first evaluation of the G-8 geriatric screening tool","volume":"23","author":"Bellera","year":"2012","journal-title":"Ann Oncol"},{"key":"10.1093\/annonc\/mdx413_bb0130","doi-asserted-by":"crossref","first-page":"1101","DOI":"10.1056\/NEJMoa1313984","article-title":"Obinutuzumab plus chlorambucil in patients with CLL and coexisting conditions","volume":"370","author":"Goede","year":"2014","journal-title":"N Engl J Med"},{"key":"10.1093\/annonc\/mdx413_bb0135","doi-asserted-by":"crossref","first-page":"218","DOI":"10.1093\/annonc\/mdw547","article-title":"Management of chronic lymphocytic leukemia (CLL) in the elderly: a position paper from an International Society of Geriatric Oncology (SIOG) Task Force","volume":"28","author":"Stauder","year":"2017","journal-title":"Ann Oncol"},{"key":"10.1093\/annonc\/mdx413_bb0140","doi-asserted-by":"crossref","first-page":"891","DOI":"10.1007\/s40266-015-0312-7","article-title":"Myelodysplastic syndromes in the elderly: treatment options and personalized management","volume":"32","author":"Burgstaller","year":"2015","journal-title":"Drugs Aging"},{"key":"10.1093\/annonc\/mdx413_bb0145","doi-asserted-by":"crossref","first-page":"2541","DOI":"10.1200\/JCO.2014.55.1564","article-title":"Acute myeloid leukemia and myelodysplastic syndromes in older adults","volume":"32","author":"Klepin","year":"2014","journal-title":"J Clin Oncol"},{"key":"10.1093\/annonc\/mdx413_bb0150","doi-asserted-by":"crossref","first-page":"3600","DOI":"10.1200\/JCO.2016.68.6113","article-title":"Optimizing treatment for elderly patients with newly diagnosed multiple myeloma: a personalized approach","volume":"34","author":"Larocca","year":"2016","journal-title":"J Clin Oncol"},{"key":"10.1093\/annonc\/mdx413_bb0155","doi-asserted-by":"crossref","DOI":"10.1093\/jnci\/dju321","article-title":"Words matter: distinguishing \u201cpersonalized medicine\u201d and \u201cbiologically personalized therapeutics\u201d","volume":"106","author":"Cherny","year":"2014","journal-title":"J Natl Cancer Inst"},{"key":"10.1093\/annonc\/mdx413_bb0160","doi-asserted-by":"crossref","first-page":"1766","DOI":"10.1093\/jnci\/86.23.1766","article-title":"Age and clinical decision making in oncology patients","volume":"86","author":"Yellen","year":"1994","journal-title":"J Natl Cancer Inst"},{"key":"10.1093\/annonc\/mdx413_bb0165","doi-asserted-by":"crossref","first-page":"812","DOI":"10.1016\/j.ctrv.2013.01.007","article-title":"Barriers to inclusion of older adults in randomised controlled clinical trials on Non-Hodgkin's lymphoma: a systematic review","volume":"39","author":"Bellera","year":"2013","journal-title":"Cancer Treat Rev"},{"key":"10.1093\/annonc\/mdx413_bb0170","doi-asserted-by":"crossref","first-page":"865","DOI":"10.1016\/S1470-2045(09)70200-1","article-title":"Baseline quality of life as a prognostic indicator of survival: a meta-analysis of individual patient data from EORTC clinical trials","volume":"10","author":"Quinten","year":"2009","journal-title":"Lancet Oncol"},{"key":"10.1093\/annonc\/mdx413_bb0175","doi-asserted-by":"crossref","first-page":"3877","DOI":"10.1200\/JCO.2012.47.7430","article-title":"Functional decline in older patients with cancer receiving first-line chemotherapy","volume":"31","author":"Hoppe","year":"2013","journal-title":"J Clin Oncol"},{"key":"10.1093\/annonc\/mdx413_bb0180","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1016\/j.critrevonc.2010.10.003","article-title":"Impact of liposomal doxorubicin-based adjuvant chemotherapy on autonomy in women over 70 with hormone-receptor-negative breast carcinoma: a French Geriatric Oncology Group (GERICO) phase II multicentre trial","volume":"80","author":"Brain","year":"2011","journal-title":"Crit Rev Oncol Hematol"},{"key":"10.1093\/annonc\/mdx413_bb0185","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1002\/hec.4730020305","article-title":"The RAND 36-Item Health Survey 1.0","volume":"2","author":"Hays","year":"1993","journal-title":"Health Econ"},{"key":"10.1093\/annonc\/mdx413_bb0190","series-title":"Health Survey. Manual & Interpretation Guide","author":"Ware","year":"1993"},{"key":"10.1093\/annonc\/mdx413_bb0195","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1007\/BF00434949","article-title":"International Quality of Life Assessment (IQOLA) project","volume":"1","author":"Aaronson","year":"1992","journal-title":"Qual Life Res"},{"key":"10.1093\/annonc\/mdx413_bb0200","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1093\/jnci\/85.5.365","article-title":"The European Organization for Research and Treatment of Cancer QLQ-C30: a quality-of-life instrument for use in international clinical trials in oncology","volume":"85","author":"Aaronson","year":"1993","journal-title":"J Natl Cancer Inst"},{"key":"10.1093\/annonc\/mdx413_bb0205","doi-asserted-by":"crossref","first-page":"2242","DOI":"10.1016\/j.ejca.2010.04.014","article-title":"Development of the European Organisation for Research and Treatment of Cancer quality of life questionnaire module for older people with cancer: the EORTC QLQ-ELD15","volume":"46","author":"Johnson","year":"2010","journal-title":"Eur J Cancer"},{"key":"10.1093\/annonc\/mdx413_bb0210","doi-asserted-by":"crossref","first-page":"852","DOI":"10.1038\/bjc.2013.407","article-title":"International validation of the EORTC QLQ-ELD14 questionnaire for assessment of health-related quality of life elderly patients with cancer","volume":"109","author":"Wheelwright","year":"2013","journal-title":"Br J Cancer"},{"key":"10.1093\/annonc\/mdx413_bb0215","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1200\/JCO.2010.28.0107","article-title":"Evidence-based guidelines for determination of sample size and interpretation of the European Organisation for the Research and Treatment of Cancer Quality of Life Questionnaire Core 30","volume":"29","author":"Cocks","year":"2011","journal-title":"J Clin Oncol"},{"key":"10.1093\/annonc\/mdx413_bb0220","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1200\/JCO.1998.16.1.139","article-title":"Interpreting the significance of changes in health-related quality-of-life scores","volume":"16","author":"Osoba","year":"1998","journal-title":"J Clin Oncol"},{"issue":"Suppl","key":"10.1093\/annonc\/mdx413_bb0225","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1016\/S1359-6349(12)70023-X","article-title":"Health-related quality of life in EORTC clinical trials\u201430years of progress from methodological developments to making a real impact on oncology practice","volume":"10","author":"Velikova","year":"2012","journal-title":"Eur J Cancer"},{"key":"10.1093\/annonc\/mdx413_bb0230","doi-asserted-by":"crossref","first-page":"914","DOI":"10.1001\/jama.1963.03060120024016","article-title":"Studies of illness in the aged. The index of ADL: a standardized measure of biological and psychosocial function","volume":"185","author":"Katz","year":"1963","journal-title":"JAMA"},{"key":"10.1093\/annonc\/mdx413_bb0235","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1093\/geront\/9.3_Part_1.179","article-title":"Assessment of older people: self-maintaining and instrumental activities of daily living","volume":"9","author":"Lawton","year":"1969","journal-title":"Gerontologist"},{"key":"10.1093\/annonc\/mdx413_bb0240","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1080\/10428190701724785","article-title":"Comorbid conditions and survival in unselected, newly diagnosed patients with chronic lymphocytic leukemia","volume":"49","author":"Thurmes","year":"2008","journal-title":"Leuk Lymphoma"},{"key":"10.1093\/annonc\/mdx413_bb0245","doi-asserted-by":"crossref","first-page":"1599","DOI":"10.3324\/haematol.2014.107326","article-title":"Chronic lymphocytic leukemia in the elderly: clinico-biological features, outcomes, and proposal of a prognostic model","volume":"99","author":"Baumann","year":"2014","journal-title":"Haematologica"},{"key":"10.1093\/annonc\/mdx413_bb0250","doi-asserted-by":"crossref","first-page":"1095","DOI":"10.3324\/haematol.2013.096792","article-title":"Interactions between comorbidity and treatment of chronic lymphocytic leukemia: results of German Chronic Lymphocytic Leukemia Study Group trials","volume":"99","author":"Goede","year":"2014","journal-title":"Haematologica"},{"key":"10.1093\/annonc\/mdx413_bb0255","doi-asserted-by":"crossref","first-page":"789","DOI":"10.3109\/10428194.2015.1091933","article-title":"Evaluation of geriatric assessment in patients with chronic lymphocytic leukemia: results of the CLL9 trial of the German CLL study group","volume":"57","author":"Goede","year":"2016","journal-title":"Leuk Lymphoma"},{"key":"10.1093\/annonc\/mdx413_bb0260","doi-asserted-by":"crossref","first-page":"1335","DOI":"10.1007\/s00277-014-2048-6","article-title":"Treatment practice in the elderly patient with chronic lymphocytic leukemia-analysis of the combined SEER and Medicare database","volume":"93","author":"Satram-Hoang","year":"2014","journal-title":"Ann Hematol"},{"issue":"Suppl 4","key":"10.1093\/annonc\/mdx413_bb0265","first-page":"iv149","article-title":"Appendix 4: Chronic lymphocytic leukaemia: eUpdate published online 27 June 2017","volume":"28","author":"ESMO Guidelines Committee","year":"2017","journal-title":"Ann Oncol"},{"key":"10.1093\/annonc\/mdx413_bb0270","doi-asserted-by":"crossref","first-page":"5446","DOI":"10.1182\/blood-2007-06-093906","article-title":"Guidelines for the diagnosis and treatment of chronic lymphocytic leukemia: a report from the International Workshop on Chronic Lymphocytic Leukemia updating the National Cancer Institute-Working Group 1996 guidelines","volume":"111","author":"Hallek","year":"2008","journal-title":"Blood"},{"key":"10.1093\/annonc\/mdx413_bb0275","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1016\/j.leukres.2013.12.018","article-title":"The relevance of a geriatric assessment for elderly patients with a haematological malignancy--a systematic review","volume":"38","author":"Hamaker","year":"2014","journal-title":"Leuk Res"},{"key":"10.1093\/annonc\/mdx413_bb0280","doi-asserted-by":"crossref","first-page":"1164","DOI":"10.1016\/S0140-6736(10)61381-5","article-title":"Addition of rituximab to fludarabine and cyclophosphamide in patients with chronic lymphocytic leukaemia: a randomised, open-label, phase 3 trial","volume":"376","author":"Hallek","year":"2010","journal-title":"Lancet"},{"key":"10.1093\/annonc\/mdx413_bb0285","doi-asserted-by":"crossref","first-page":"4079","DOI":"10.1200\/JCO.2005.12.051","article-title":"Early results of a chemoimmunotherapy regimen of fludarabine, cyclophosphamide, and rituximab as initial therapy for chronic lymphocytic leukemia","volume":"23","author":"Keating","year":"2005","journal-title":"J Clin Oncol"},{"key":"10.1093\/annonc\/mdx413_bb0290","doi-asserted-by":"crossref","first-page":"1756","DOI":"10.1200\/JCO.2009.26.4556","article-title":"Rituximab plus fludarabine and cyclophosphamide prolongs progression-free survival compared with fludarabine and cyclophosphamide alone in previously treated chronic lymphocytic leukemia","volume":"28","author":"Robak","year":"2010","journal-title":"J Clin Oncol"},{"key":"10.1093\/annonc\/mdx413_bb0295","doi-asserted-by":"crossref","first-page":"928","DOI":"10.1016\/S1470-2045(16)30051-1","article-title":"First-line chemoimmunotherapy with bendamustine and rituximab versus fludarabine, cyclophosphamide, and rituximab in patients with advanced chronic lymphocytic leukaemia (CLL10): an international, open-label, randomised, phase 3, non-inferiority trial","volume":"17","author":"Eichhorst","year":"2016","journal-title":"Lancet Oncol"},{"key":"10.1093\/annonc\/mdx413_bb0300","doi-asserted-by":"crossref","first-page":"3209","DOI":"10.1200\/JCO.2011.39.2688","article-title":"Bendamustine in combination with rituximab for previously untreated patients with chronic lymphocytic leukemia: a multicenter phase II trial of the German Chronic Lymphocytic Leukemia Study Group","volume":"30","author":"Fischer","year":"2012","journal-title":"J Clin Oncol"},{"key":"10.1093\/annonc\/mdx413_bb0305","doi-asserted-by":"crossref","first-page":"3325","DOI":"10.1182\/blood.V124.21.3325.3325","article-title":"A randomised dose de-escalation study of oral fludarabine, \u00b1oral cyclophosphamide and intravenous rituximab as first-line therapy of fit patients with chronic lymphocytic leukaemia (CLL) aged \u226565years: final analysis of response and toxicity","volume":"124","author":"Mulligan","year":"2014","journal-title":"Blood"},{"key":"10.1093\/annonc\/mdx413_bb0310","doi-asserted-by":"crossref","first-page":"1044","DOI":"10.3109\/10428194.2015.1096353","article-title":"Dose-reduced fludarabine, cyclophosphamide and rituximab is well tolerated in older patients with chronic lymphocytic leukemia and has preserved therapeutic efficacy","volume":"57","author":"Lew","year":"2016","journal-title":"Leuk Lymphoma"},{"key":"10.1093\/annonc\/mdx413_bb0315","doi-asserted-by":"crossref","first-page":"1873","DOI":"10.1016\/S0140-6736(15)60027-7","article-title":"Chlorambucil plus ofatumumab versus chlorambucil alone in previously untreated patients with chronic lymphocytic leukaemia (COMPLEMENT 1): a randomised, multicentre, open-label phase 3 trial","volume":"385","author":"Hillmen","year":"2015","journal-title":"Lancet"},{"key":"10.1093\/annonc\/mdx413_bb0320","doi-asserted-by":"crossref","first-page":"4670","DOI":"10.1182\/blood.V124.21.4670.4670","article-title":"Low-dose FCR is a safe and effective treatment option for elderly\/comorbid patients with chronic lymphocytic leukemia\/small lymphocytic lymphoma. Updated results of project Q-Lite By Czech CLL Study Group","volume":"124","author":"Smolej","year":"2014","journal-title":"Blood"},{"key":"10.1093\/annonc\/mdx413_bb0325","author":"Michallet","year":"2015","journal-title":"Rituximab in combination with bendamustine or chlorambucil for the treatment of chronic lymphocytic leukaemia primary results from the randomised phase IIIb MABLE study In XVI International Workshop on Chronic Lymphocytic Leukaemia Sydney Australia"},{"key":"10.1093\/annonc\/mdx413_bb0330","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1016\/S1470-2045(14)71182-9","article-title":"Ibrutinib for previously untreated and relapsed or refractory chronic lymphocytic leukaemia with TP53 aberrations: a phase 2, single-arm trial","volume":"16","author":"Farooqui","year":"2015","journal-title":"Lancet Oncol"},{"key":"10.1093\/annonc\/mdx413_bb0335","doi-asserted-by":"crossref","first-page":"2425","DOI":"10.1056\/NEJMoa1509388","article-title":"Ibrutinib as initial therapy for patients with chronic lymphocytic leukemia","volume":"373","author":"Burger","year":"2015","journal-title":"N Engl J Med"},{"key":"10.1093\/annonc\/mdx413_bb0340","doi-asserted-by":"crossref","first-page":"997","DOI":"10.1056\/NEJMoa1315226","article-title":"Idelalisib and rituximab in relapsed chronic lymphocytic leukemia","volume":"370","author":"Furman","year":"2014","journal-title":"N Engl J Med"},{"key":"10.1093\/annonc\/mdx413_bb0345","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1056\/NEJMoa1400376","article-title":"Ibrutinib versus ofatumumab in previously treated chronic lymphoid leukemia","volume":"371","author":"Byrd","year":"2014","journal-title":"N Engl J Med"},{"key":"10.1093\/annonc\/mdx413_bb0350","doi-asserted-by":"crossref","first-page":"768","DOI":"10.1016\/S1470-2045(16)30019-5","article-title":"Venetoclax in relapsed or refractory chronic lymphocytic leukaemia with 17p deletion: a multicentre, open-label, phase 2 study","volume":"17","author":"Stilgenbauer","year":"2016","journal-title":"Lancet Oncol"},{"key":"10.1093\/annonc\/mdx413_bb0355","doi-asserted-by":"crossref","first-page":"1202","DOI":"10.1200\/JCO.2008.18.1495","article-title":"Follicular lymphoma in the United States: first report of the national LymphoCare study","volume":"27","author":"Friedberg","year":"2009","journal-title":"J Clin Oncol"},{"key":"10.1093\/annonc\/mdx413_bb0360","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1007\/s002770050521","article-title":"Prevalence of co-morbidity and its relationship to treatment among unselected patients with Hodgkin's disease and non-Hodgkin's lymphoma, 1993-1996","volume":"78","author":"van Spronsen","year":"1999","journal-title":"Ann Hematol"},{"key":"10.1093\/annonc\/mdx413_bb0365","doi-asserted-by":"crossref","first-page":"4480","DOI":"10.1200\/JCO.2010.28.4786","article-title":"Long-term follow-up of patients with follicular lymphoma receiving single-agent rituximab at two different schedules in trial SAKK 35\/98","volume":"28","author":"Martinelli","year":"2010","journal-title":"J Clin Oncol"},{"key":"10.1093\/annonc\/mdx413_bb0370","doi-asserted-by":"crossref","first-page":"1525","DOI":"10.1158\/1078-0432.CCR-14-2522","article-title":"FDA approval: idelalisib monotherapy for the treatment of patients with follicular lymphoma and small lymphocytic lymphoma","volume":"21","author":"Miller","year":"2015","journal-title":"Clin Cancer Res"},{"key":"10.1093\/annonc\/mdx413_bb0375","doi-asserted-by":"crossref","first-page":"1110","DOI":"10.1200\/JCO.1997.15.3.1110","article-title":"Comparison in low-tumor-burden follicular lymphomas between an initial no-treatment policy, prednimustine, or interferon alfa: a randomized study from the Groupe d'Etude des Lymphomes Folliculaires. Groupe d'Etude des Lymphomes de l'Adulte","volume":"15","author":"Brice","year":"1997","journal-title":"J Clin Oncol"},{"key":"10.1093\/annonc\/mdx413_bb0380","doi-asserted-by":"crossref","first-page":"2453","DOI":"10.1200\/JCO.2002.11.076","article-title":"Randomized controlled trial of yttrium-90-labeled ibritumomab tiuxetan radioimmunotherapy versus rituximab immunotherapy for patients with relapsed or refractory low-grade, follicular, or transformed B-cell non-Hodgkin's lymphoma","volume":"20","author":"Witzig","year":"2002","journal-title":"J Clin Oncol"},{"key":"10.1093\/annonc\/mdx413_bb0385","doi-asserted-by":"crossref","first-page":"1977","DOI":"10.1200\/JCO.2012.45.6400","article-title":"90Yttrium-ibritumomab tiuxetan consolidation of first remission in advanced-stage follicular non-Hodgkin lymphoma: updated results after a median follow-up of 7.3years from the International, Randomized, Phase III First-Line Indolent trial","volume":"31","author":"Morschhauser","year":"2013","journal-title":"J Clin Oncol"},{"key":"10.1093\/annonc\/mdx413_bb0390","doi-asserted-by":"crossref","first-page":"1207","DOI":"10.1182\/blood-2014-06-578872","article-title":"How to treat old MCL patients: one size fits it all?","volume":"124","author":"Dreyling","year":"2014","journal-title":"Blood"},{"key":"10.1093\/annonc\/mdx413_bb0395","doi-asserted-by":"crossref","first-page":"3048","DOI":"10.1200\/JCO.2013.53.5229","article-title":"Role of imaging in the staging and response assessment of lymphoma: consensus of the International Conference on Malignant Lymphomas Imaging Working Group","volume":"32","author":"Barrington","year":"2014","journal-title":"J Clin Oncol"},{"key":"10.1093\/annonc\/mdx413_bb0400","doi-asserted-by":"crossref","first-page":"520","DOI":"10.1056\/NEJMoa1200920","article-title":"Treatment of older patients with mantle-cell lymphoma","volume":"367","author":"Kluin-Nelemans","year":"2012","journal-title":"N Engl J Med"},{"key":"10.1093\/annonc\/mdx413_bb0405","doi-asserted-by":"crossref","first-page":"1203","DOI":"10.1016\/S0140-6736(12)61763-2","article-title":"Bendamustine plus rituximab versus CHOP plus rituximab as first-line treatment for patients with indolent and mantle-cell lymphomas: an open-label, multicentre, randomised, phase 3 non-inferiority trial","volume":"381","author":"Rummel","year":"2013","journal-title":"Lancet"},{"key":"10.1093\/annonc\/mdx413_bb0410","doi-asserted-by":"crossref","first-page":"2944","DOI":"10.1182\/blood-2013-11-531327","article-title":"Randomized trial of bendamustine-rituximab or R-CHOP\/R-CVP in first-line treatment of indolent NHL or MCL: the BRIGHT study","volume":"123","author":"Flinn","year":"2014","journal-title":"Blood"},{"key":"10.1093\/annonc\/mdx413_bb0415","doi-asserted-by":"crossref","first-page":"944","DOI":"10.1056\/NEJMoa1412096","article-title":"Bortezomib-based therapy for newly diagnosed mantle-cell lymphoma","volume":"372","author":"Robak","year":"2015","journal-title":"N Engl J Med"},{"key":"10.1093\/annonc\/mdx413_bb0420","doi-asserted-by":"crossref","first-page":"1442","DOI":"10.1200\/JCO.2012.45.9842","article-title":"Combination of rituximab, bendamustine, and cytarabine for patients with mantle-cell non-Hodgkin lymphoma ineligible for intensive regimens or autologous transplantation","volume":"31","author":"Visco","year":"2013","journal-title":"J Clin Oncol"},{"key":"10.1093\/annonc\/mdx413_bb0425","doi-asserted-by":"crossref","first-page":"e15","DOI":"10.1016\/S2352-3026(16)30185-5","article-title":"Rituximab, bendamustine, and low-dose cytarabine as induction therapy in elderly patients with mantle cell lymphoma: a multicentre, phase 2 trial from Fondazione Italiana Linfomi","volume":"4","author":"Visco","year":"2017","journal-title":"Lancet Haematol"},{"key":"10.1093\/annonc\/mdx413_bb0430","unstructured":"NCT01865110. R-CHOP+R-HAD vs R-CHOP followed by maintenance lenalidomide + rituximab vs rituximab for older patients with MCL 2016; https:\/\/clinicaltrials.gov\/ct2\/show\/NCT01865110?term=NCT01865110&rank=1 (22 November 2016, date last accessed)."},{"key":"10.1093\/annonc\/mdx413_bb0435","doi-asserted-by":"crossref","first-page":"338","DOI":"10.1111\/j.1365-2141.2005.05777.x","article-title":"Activity and safety of combined rituximab with chlorambucil in patients with mantle cell lymphoma","volume":"131","author":"Bauwens","year":"2005","journal-title":"Br J Haematol"},{"key":"10.1093\/annonc\/mdx413_bb0440","doi-asserted-by":"crossref","first-page":"387","DOI":"10.3109\/10428194.2010.534518","article-title":"Combination of rituximab with chlorambucil as first line treatment in patients with mantle cell lymphoma: a highly effective regimen","volume":"52","author":"Sachanas","year":"2011","journal-title":"Leuk Lymphoma"},{"issue":"Suppl 1","key":"10.1093\/annonc\/mdx413_bb0445","doi-asserted-by":"crossref","first-page":"S90","DOI":"10.1179\/102453312X13336169155970","article-title":"Metronomic therapy for refractory\/relapsed lymphoma: the PEP-C low-dose oral combination chemotherapy regimen","volume":"17","author":"Coleman","year":"2012","journal-title":"Hematology"},{"key":"10.1093\/annonc\/mdx413_bb0450","doi-asserted-by":"crossref","first-page":"705","DOI":"10.1200\/JCO.2005.04.164","article-title":"Effect of single-agent rituximab given at the standard schedule or as prolonged treatment in patients with mantle cell lymphoma: a study of the Swiss Group for Clinical Cancer Research (SAKK)","volume":"23","author":"Ghielmini","year":"2005","journal-title":"J Clin Oncol"},{"key":"10.1093\/annonc\/mdx413_bb0455","doi-asserted-by":"crossref","first-page":"1835","DOI":"10.1056\/NEJMoa1505237","article-title":"Lenalidomide plus rituximab as initial treatment for mantle-cell lymphoma","volume":"373","author":"Ruan","year":"2015","journal-title":"N Engl J Med"},{"key":"10.1093\/annonc\/mdx413_bb0460","doi-asserted-by":"crossref","first-page":"739","DOI":"10.1182\/blood-2015-03-635326","article-title":"Long-term follow-up of MCL patients treated with single-agent ibrutinib: updated safety and efficacy results","volume":"126","author":"Wang","year":"2015","journal-title":"Blood"},{"key":"10.1093\/annonc\/mdx413_bb0465","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1056\/NEJMoa1306220","article-title":"Targeting BTK with ibrutinib in relapsed or refractory mantle-cell lymphoma","volume":"369","author":"Wang","year":"2013","journal-title":"N Engl J Med"},{"key":"10.1093\/annonc\/mdx413_bb0470","doi-asserted-by":"crossref","first-page":"770","DOI":"10.1016\/S0140-6736(15)00667-4","article-title":"Ibrutinib versus temsirolimus in patients with relapsed or refractory mantle-cell lymphoma: an international, randomised, open-label, phase 3 study","volume":"387","author":"Dreyling","year":"2016","journal-title":"Lancet"},{"key":"10.1093\/annonc\/mdx413_bb0475","doi-asserted-by":"crossref","first-page":"716","DOI":"10.1016\/S1470-2045(12)70200-0","article-title":"Lenalidomide in combination with rituximab for patients with relapsed or refractory mantle-cell lymphoma: a phase 1\/2 clinical trial","volume":"13","author":"Wang","year":"2012","journal-title":"Lancet Oncol"},{"key":"10.1093\/annonc\/mdx413_bb0480","doi-asserted-by":"crossref","first-page":"3822","DOI":"10.1200\/JCO.2008.20.7977","article-title":"Phase III study to evaluate temsirolimus compared with investigator's choice therapy for the treatment of relapsed or refractory mantle cell lymphoma","volume":"27","author":"Hess","year":"2009","journal-title":"J Clin Oncol"},{"key":"10.1093\/annonc\/mdx413_bb0485","doi-asserted-by":"crossref","first-page":"4867","DOI":"10.1200\/JCO.2006.07.9665","article-title":"Multicenter phase II study of bortezomib in patients with relapsed or refractory mantle cell lymphoma","volume":"24","author":"Fisher","year":"2006","journal-title":"J Clin Oncol"},{"key":"10.1093\/annonc\/mdx413_bb0490","doi-asserted-by":"crossref","first-page":"4124","DOI":"10.1200\/JCO.2008.16.4558","article-title":"International peripheral T-cell and natural killer\/T-cell lymphoma study: pathology findings and clinical outcomes","volume":"26","author":"Vose","year":"2008","journal-title":"J Clin Oncol"},{"key":"10.1093\/annonc\/mdx413_bb0495","doi-asserted-by":"crossref","first-page":"2211","DOI":"10.1093\/annonc\/mdu443","article-title":"Peripheral T-cell lymphomas in a large US multicenter cohort: prognostication in the modern era including impact of frontline therapy","volume":"25","author":"Abramson","year":"2014","journal-title":"Ann Oncol"},{"key":"10.1093\/annonc\/mdx413_bb0500","doi-asserted-by":"crossref","first-page":"5019","DOI":"10.1182\/blood-2011-01-293050","article-title":"The 2008 WHO classification of lymphoid neoplasms and beyond: evolving concepts and practical applications","volume":"117","author":"Campo","year":"2011","journal-title":"Blood"},{"key":"10.1093\/annonc\/mdx413_bb0505","doi-asserted-by":"crossref","first-page":"490","DOI":"10.1097\/00000478-200604000-00009","article-title":"Expression of CXCL13 by neoplastic cells in angioimmunoblastic T-cell lymphoma (AITL): a new diagnostic marker providing evidence that AITL derives from follicular helper T cells","volume":"30","author":"Dupuis","year":"2006","journal-title":"Am J Surg Pathol"},{"key":"10.1093\/annonc\/mdx413_bb0510","doi-asserted-by":"crossref","first-page":"1787","DOI":"10.1097\/PAS.0b013e31817f123e","article-title":"Peripheral T-cell lymphoma with follicular T-cell markers","volume":"32","author":"Rodr\u00edguez-Pinilla","year":"2008","journal-title":"Am J Surg Pathol"},{"key":"10.1093\/annonc\/mdx413_bb0515","doi-asserted-by":"crossref","first-page":"333","DOI":"10.2214\/AJR.09.3665","article-title":"Characterization of T-cell lymphomas by FDG PET\/CT","volume":"195","author":"Feeney","year":"2010","journal-title":"AJR Am J Roentgenol"},{"key":"10.1093\/annonc\/mdx413_bb0520","doi-asserted-by":"crossref","first-page":"3402","DOI":"10.1182\/blood-2010-09-310342","article-title":"Peripheral T-cell lymphoma, not otherwise specified: a report of 340 cases from the International Peripheral T-cell Lymphoma Project","volume":"117","author":"Weisenburger","year":"2011","journal-title":"Blood"},{"key":"10.1093\/annonc\/mdx413_bb0525","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1007\/s00280-007-0469-9","article-title":"Alemtuzumab plus CHOP as front-line chemotherapy for patients with peripheral T-cell lymphomas: a phase II study","volume":"60","author":"Kim","year":"2007","journal-title":"Cancer Chemother Pharmacol"},{"key":"10.1093\/annonc\/mdx413_bb0530","doi-asserted-by":"crossref","first-page":"3418","DOI":"10.1182\/blood-2010-02-270785","article-title":"Treatment and prognosis of mature T-cell and NK-cell lymphoma: an analysis of patients with T-cell lymphoma treated in studies of the German High-Grade Non-Hodgkin Lymphoma Study Group","volume":"116","author":"Schmitz","year":"2010","journal-title":"Blood"},{"key":"10.1093\/annonc\/mdx413_bb0535","doi-asserted-by":"crossref","first-page":"3093","DOI":"10.1200\/JCO.2011.40.2719","article-title":"Up-front autologous stem-cell transplantation in peripheral T-cell lymphoma: NLG-T-01","volume":"30","author":"d'Amore","year":"2012","journal-title":"J Clin Oncol"},{"key":"10.1093\/annonc\/mdx413_bb0540","doi-asserted-by":"crossref","first-page":"715","DOI":"10.1093\/annonc\/mdn696","article-title":"The International Prognostic Index predicts outcome in aggressive adult T-cell leukemia\/lymphoma: analysis of 126 patients from the International Peripheral T-Cell Lymphoma Project","volume":"20","author":"Suzumiya","year":"2009","journal-title":"Ann Oncol"},{"key":"10.1093\/annonc\/mdx413_bb0545","doi-asserted-by":"crossref","first-page":"2190","DOI":"10.1200\/JCO.2011.38.0402","article-title":"Brentuximab vedotin (SGN-35) in patients with relapsed or refractory systemic anaplastic large-cell lymphoma: results of a phase II study","volume":"30","author":"Pro","year":"2012","journal-title":"J Clin Oncol"},{"key":"10.1093\/annonc\/mdx413_bb0550","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1053\/j.seminoncol.2003.12.024","article-title":"Cancer in older persons: an international issue in an aging world","volume":"31","author":"Yancik","year":"2004","journal-title":"Semin Oncol"},{"key":"10.1093\/annonc\/mdx413_bb0555","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1016\/j.jgo.2012.12.001","article-title":"Factors affecting survival in patients aged 60 and over with diffuse large B cell lymphoma failing first-line therapy","volume":"4","author":"Lowry","year":"2013","journal-title":"J Geriatr Oncol"},{"key":"10.1093\/annonc\/mdx413_bb0560","doi-asserted-by":"crossref","first-page":"2667","DOI":"10.1002\/1097-0142(20001215)89:12<2667::AID-CNCR21>3.0.CO;2-P","article-title":"Different age limits for elderly patients with indolent and aggressive non-Hodgkin lymphoma and the role of relative survival with increasing age","volume":"89","author":"Maartense","year":"2000","journal-title":"Cancer"},{"key":"10.1093\/annonc\/mdx413_bb0565","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1016\/S1470-2045(08)70002-0","article-title":"Six versus eight cycles of bi-weekly CHOP-14 with or without rituximab in elderly patients with aggressive CD20+ B-cell lymphomas: a randomised controlled trial (RICOVER-60)","volume":"9","author":"Pfreundschuh","year":"2008","journal-title":"Lancet Oncol"},{"key":"10.1093\/annonc\/mdx413_bb0570","doi-asserted-by":"crossref","first-page":"3452","DOI":"10.1200\/JCO.2011.41.0985","article-title":"Concurrent expression of MYC and BCL2 in diffuse large B-cell lymphoma treated with rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone","volume":"30","author":"Johnson","year":"2012","journal-title":"J Clin Oncol"},{"key":"10.1093\/annonc\/mdx413_bb0575","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1111\/j.1365-2141.2010.08331.x","volume":"151","author":"Advani","year":"2010","journal-title":"Br J Haematol"},{"key":"10.1093\/annonc\/mdx413_bb0580","doi-asserted-by":"crossref","first-page":"e102594.","DOI":"10.1371\/journal.pone.0102594","article-title":"A new prognostic score for elderly patients with diffuse large B-cell lymphoma treated with R-CHOP: the prognostic role of blood monocyte and lymphocyte counts is absent","volume":"9","author":"Proch\u00e1zka","year":"2014","journal-title":"PLoS One"},{"key":"10.1093\/annonc\/mdx413_bb0585","doi-asserted-by":"crossref","first-page":"525","DOI":"10.1016\/S1470-2045(13)70122-0","article-title":"Dose-dense rituximab-CHOP compared with standard rituximab-CHOP in elderly patients with diffuse large B-cell lymphoma (the LNH03-6B study): a randomised phase 3 trial","volume":"14","author":"Delarue","year":"2013","journal-title":"Lancet Oncol"},{"key":"10.1093\/annonc\/mdx413_bb0590","doi-asserted-by":"crossref","first-page":"1121","DOI":"10.6004\/jnccn.2016.0121","article-title":"Risk factors for early death after rituximab-based immunochemotherapy in older patients with diffuse large B-cell lymphoma","volume":"14","author":"Olszewski","year":"2016","journal-title":"J Natl Compr Canc Netw"},{"key":"10.1093\/annonc\/mdx413_bb0595","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1111\/bjh.13619","article-title":"Results of a large retrospective analysis of the effect of intended dose intensity of R-CHOP on outcome in a cohort of consecutive, unselected elderly patients with de novo diffuse large B cell lymphoma","volume":"173","author":"Eyre","year":"2016","journal-title":"Br J Haematol"},{"key":"10.1093\/annonc\/mdx413_bb0600","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1016\/j.jgo.2015.01.003","article-title":"Comparative effectiveness of anthracycline-containing chemotherapy in United States veterans age 80 and older with diffuse large B-cell lymphoma","volume":"6","author":"Carson","year":"2015","journal-title":"J Geriatr Oncol"},{"key":"10.1093\/annonc\/mdx413_bb0605","doi-asserted-by":"crossref","first-page":"460","DOI":"10.1016\/S1470-2045(11)70069-9","article-title":"Attenuated immunochemotherapy regimen (R-miniCHOP) in elderly patients older than 80 years with diffuse large B-cell lymphoma: a multicentre, single-arm, phase 2 trial","volume":"12","author":"Peyrade","year":"2011","journal-title":"Lancet Oncol"},{"key":"10.1093\/annonc\/mdx413_bb0610","doi-asserted-by":"crossref","first-page":"e46","DOI":"10.1016\/S2352-3026(16)30171-5","article-title":"Combination of ofatumumab and reduced-dose CHOP for diffuse large B-cell lymphomas in patients aged 80 years or older: an open-label, multicentre, single-arm, phase 2 trial from the LYSA group","volume":"4","author":"Peyrade","year":"2017","journal-title":"Lancet Haematol"},{"key":"10.1093\/annonc\/mdx413_bb0615","doi-asserted-by":"crossref","first-page":"282","DOI":"10.1200\/JCO.2013.49.7586","article-title":"De novo treatment of diffuse large B-cell lymphoma with rituximab, cyclophosphamide, vincristine, gemcitabine, and prednisolone in patients with cardiac comorbidity: a United Kingdom National Cancer Research Institute trial","volume":"32","author":"Fields","year":"2014","journal-title":"J Clin Oncol"},{"key":"10.1093\/annonc\/mdx413_bb0620","doi-asserted-by":"crossref","first-page":"1492","DOI":"10.1093\/annonc\/mdp544","article-title":"Nonpegylated liposomal doxorubicin (MyocetTM) combination (R-COMP) chemotherapy in elderly patients with diffuse large B-cell lymphoma (DLBCL): results from the phase II EUR018 trial","volume":"21","author":"Luminari","year":"2010","journal-title":"Ann Oncol"},{"key":"10.1093\/annonc\/mdx413_bb0625","doi-asserted-by":"crossref","first-page":"1112","DOI":"10.1200\/JCO.2013.51.4505","article-title":"Role of radiotherapy to bulky disease in elderly patients with aggressive B-cell lymphoma","volume":"32","author":"Held","year":"2014","journal-title":"J Clin Oncol"},{"key":"10.1093\/annonc\/mdx413_bb0630","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1016\/j.jgo.2014.11.004","article-title":"Diffuse large B-cell lymphoma in the elderly: impact of prognosis, comorbidities, geriatric assessment, and supportive care on clinical practice. An International Society of Geriatric Oncology (SIOG) expert position paper","volume":"6","author":"Morrison","year":"2015","journal-title":"J Geriatr Oncol"},{"key":"10.1093\/annonc\/mdx413_bb0635","doi-asserted-by":"crossref","first-page":"838","DOI":"10.1634\/theoncologist.2011-0417","article-title":"Modulated chemotherapy according to modified comprehensive geriatric assessment in 100 consecutive elderly patients with diffuse large B-cell lymphoma","volume":"17","author":"Spina","year":"2012","journal-title":"Oncologist"},{"key":"10.1093\/annonc\/mdx413_bb0640","doi-asserted-by":"crossref","first-page":"3242","DOI":"10.1200\/JCO.2013.53.4537","article-title":"Vitamin D deficiency impairs rituximab-mediated cellular cytotoxicity and outcome of patients with diffuse large B-cell lymphoma treated with but not without rituximab","volume":"32","author":"Bittenbring","year":"2014","journal-title":"J Clin Oncol"},{"key":"10.1093\/annonc\/mdx413_bb0645","doi-asserted-by":"crossref","first-page":"640","DOI":"10.1182\/blood-2013-07-517037","article-title":"Suboptimal dosing of rituximab in male and female patients with DLBCL","volume":"123","author":"Pfreundschuh","year":"2014","journal-title":"Blood"},{"key":"10.1093\/annonc\/mdx413_bb0650","doi-asserted-by":"crossref","first-page":"4184","DOI":"10.1200\/JCO.2010.28.1618","article-title":"Salvage regimens with autologous transplantation for relapsed large B-cell lymphoma in the rituximab era","volume":"28","author":"Gisselbrecht","year":"2010","journal-title":"J Clin Oncol"},{"key":"10.1093\/annonc\/mdx413_bb0655","doi-asserted-by":"crossref","first-page":"3490","DOI":"10.1200\/JCO.2013.53.9593","article-title":"Randomized comparison of gemcitabine, dexamethasone, and cisplatin versus dexamethasone, cytarabine, and cisplatin chemotherapy before autologous stem-cell transplantation for relapsed and refractory aggressive lymphomas: NCIC-CTG LY.12","volume":"32","author":"Crump","year":"2014","journal-title":"J Clin Oncol"},{"key":"10.1093\/annonc\/mdx413_bb0660","doi-asserted-by":"crossref","first-page":"1726","DOI":"10.3324\/haematol.2013.090597","article-title":"Rituximab plus gemcitabine and oxaliplatin in patients with refractory\/relapsed diffuse large B-cell lymphoma who are not candidates for high-dose therapy. A phase II Lymphoma Study Association trial","volume":"98","author":"Mounier","year":"2013","journal-title":"Haematologica"},{"key":"10.1093\/annonc\/mdx413_bb0665","doi-asserted-by":"crossref","first-page":"1823","DOI":"10.3109\/10428194.2015.1106536","article-title":"Safety and efficacy of rituximab plus bendamustine in relapsed or refractory diffuse large B-cell lymphoma patients: an Italian retrospective multicenter study","volume":"57","author":"Arcari","year":"2016","journal-title":"Leuk Lymphoma"},{"key":"10.1093\/annonc\/mdx413_bb0670","doi-asserted-by":"crossref","first-page":"696","DOI":"10.1016\/S1470-2045(12)70212-7","article-title":"Pixantrone dimaleate versus other chemotherapeutic agents as a single-agent salvage treatment in patients with relapsed or refractory aggressive non-Hodgkin lymphoma: a phase 3, multicentre, open-label, randomised trial","volume":"13","author":"Pettengell","year":"2012","journal-title":"Lancet Oncol"},{"key":"10.1093\/annonc\/mdx413_bb0675","doi-asserted-by":"crossref","first-page":"e137","DOI":"10.1016\/S2352-3026(17)30016-9","article-title":"Lenalidomide maintenance in patients with relapsed diffuse large B-cell lymphoma who are not eligible for autologous stem cell transplantation: an open label, single-arm, multicentre phase 2 trial","volume":"4","author":"Ferreri","year":"2017","journal-title":"Lancet Haematol"}],"container-title":["Annals of Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0923753419354821?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0923753419354821?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/academic.oup.com\/annonc\/article-pdf\/29\/3\/544\/24530772\/mdx413.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,6,26]],"date-time":"2021-06-26T08:54:01Z","timestamp":1624697641000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0923753419354821"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,3]]},"references-count":134,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2018,3]]}},"alternative-id":["S0923753419354821"],"URL":"https:\/\/doi.org\/10.1093\/annonc\/mdx413","relation":{},"ISSN":["0923-7534"],"issn-type":[{"value":"0923-7534","type":"print"}],"subject":[],"published":{"date-parts":[[2018,3]]}}}